Geron Corporation

GERN Healthcare Biotechnology

Geron Corporation’s revenue for fiscal 2025 (year ended December 2025) was $183.9 million, up 138.8% from fiscal 2024. In the quarter to June 2026, revenue grew 17.2%, EPS was flat, free cash flow grew 41.8% and total debt was flat, each against the same quarter a year earlier.

1.17 0.06 −4.88%
Market cap
$790.2M
P/E
0.0×
Fwd P/E
−58.5×
Dividend yield
—
F-score
3/9
Altman Z
−2.24
Beneish M
−1.70
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
3 3 3 3

+8 more TTM periods

ROE
(28.28%) (27.07%) (32.99%) (29.57%)
ROA
(12.59%) (12.28%) (14.34%) (15.80%)
ROIC
(89.85%) (93.28%) 0.00% 0.00%
Return on Tangible Assets
(16.21%) (15.80%) (20.39%) (18.36%)
Average Days of Receivables
95.47 82.07 77.86 74.94
Free Cash Flow per Share
(0.17) (0.19) (0.17) (0.20)
Free Cash Flow
(114.76) (126.30) (111.09) (132.82)
Other line items

Show all line items

Columns are period end dates